Comparative Pharmacology
Head-to-head clinical analysis: FLUTAMIDE versus NILUTAMIDE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: FLUTAMIDE versus NILUTAMIDE.
FLUTAMIDE vs NILUTAMIDE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Nonsteroidal antiandrogen; competitively inhibits androgen binding to androgen receptors, thereby blocking androgen action in target tissues.
Nonsteroidal antiandrogen that competitively inhibits androgen binding to androgen receptors, blocking androgen action in target tissues.
250 mg orally every 8 hours. Total daily dose: 750 mg.
300 mg orally once daily
None Documented
None Documented
Flutamide has an initial half-life of about 5–6 hours; its active metabolite, 2-hydroxyflutamide, has a terminal elimination half-life of 8–10 hours, supporting twice-daily dosing for steady-state concentrations.
Clinical Note
moderateFlutamide + Digoxin
"Flutamide may decrease the cardiotoxic activities of Digoxin."
Clinical Note
moderateNilutamide + Digoxin
"Nilutamide may decrease the cardiotoxic activities of Digoxin."
Clinical Note
moderateFlutamide + Digitoxin
"Flutamide may decrease the cardiotoxic activities of Digitoxin."
Clinical Note
moderateNilutamide + Digitoxin
"Nilutamide may decrease the cardiotoxic activities of Digitoxin."
The terminal elimination half-life is approximately 38–56 hours (mean ~49 hours), allowing once-daily dosing. Steady-state is achieved after about 7–10 days.
Primarily renal (approximately 98% of absorbed dose as metabolites, with ~4.5% as the active metabolite 2-hydroxyflutamide); less than 1% excreted unchanged; biliary/fecal elimination is minimal (<1%).
Nilutamide is extensively metabolized; less than 2% of the dose is excreted unchanged in urine. The majority of metabolites (approximately 70%) are excreted renally, with the remainder (about 30%) eliminated in feces via biliary excretion.
Category D/X
Category C
Antiandrogen
Antiandrogen